276 related articles for article (PubMed ID: 29580231)
21. [Establishment and application of a nomogram model for prognostic risk prediction in patients with epithelial ovarian cancer].
Li Z; Cai XW; Yan P; Zhou D; He MM; Deng L; Wang YZ; Liang ZQ
Zhonghua Fu Chan Ke Za Zhi; 2022 Mar; 57(3):190-197. PubMed ID: 35385956
[No Abstract] [Full Text] [Related]
22. Clinical Significance of CA125 Level after the First Cycle of Chemotherapy on Survival of Patients with Advanced Ovarian Cancer.
Lee M; Chang MY; Yoo H; Lee KE; Chay DB; Cho H; Kim S; Kim YT; Kim JH
Yonsei Med J; 2016 May; 57(3):580-7. PubMed ID: 26996555
[TBL] [Abstract][Full Text] [Related]
23. Prognostic analysis of invasive circulating tumor cells (iCTCs) in epithelial ovarian cancer.
Pearl ML; Zhao Q; Yang J; Dong H; Tulley S; Zhang Q; Golightly M; Zucker S; Chen WT
Gynecol Oncol; 2014 Sep; 134(3):581-90. PubMed ID: 24972191
[TBL] [Abstract][Full Text] [Related]
24. The utility of presurgical CA125 to predict optimal tumor cytoreduction of epithelial ovarian cancer.
Barlow TS; Przybylski M; Schilder JM; Moore DH; Look KY
Int J Gynecol Cancer; 2006; 16(2):496-500. PubMed ID: 16681717
[TBL] [Abstract][Full Text] [Related]
25. Elevated level of serum growth differentiation factor 15 is associated with oral leukoplakia and oral squamous cell carcinoma.
Yang CZ; Ma J; Luo QQ; Neskey DM; Zhu DW; Liu Y; Myers JN; Zhang CP; Zhang ZY; Zhong LP
J Oral Pathol Med; 2014 Jan; 43(1):28-34. PubMed ID: 23710769
[TBL] [Abstract][Full Text] [Related]
26. High levels of pretreatment CA125 are associated to improved survival in high grade serous ovarian carcinoma.
Morales-Vásquez F; Pedernera E; Reynaga-Obregón J; López-Basave HN; Gómora MJ; Carlón E; Cárdenas S; Silva-Ayala R; Almaraz M; Méndez C
J Ovarian Res; 2016 Jul; 9(1):41. PubMed ID: 27388275
[TBL] [Abstract][Full Text] [Related]
27. Serum miR-125b levels associated with epithelial ovarian cancer (EOC) development and treatment responses.
Chen Z; Guo X; Sun S; Lu C; Wang L
Bioengineered; 2020 Dec; 11(1):311-317. PubMed ID: 32107956
[TBL] [Abstract][Full Text] [Related]
28. Possible use of CA-125 level normalization after the third chemotherapy cycle in deciding on chemotherapy regimen in patients with epithelial ovarian cancer: brief report.
Skaznik-Wikiel ME; Sukumvanich P; Beriwal S; Zorn KK; Kelley JL; Richard SD; Krivak TC
Int J Gynecol Cancer; 2011 Aug; 21(6):1013-7. PubMed ID: 21792011
[TBL] [Abstract][Full Text] [Related]
29. Preoperative serum CA125 levels do not predict suboptimal cytoreductive surgery in epithelial ovarian cancer.
Arits AH; Stoot JE; Botterweck AA; Roumen FJ; Voogd AC
Int J Gynecol Cancer; 2008; 18(4):621-8. PubMed ID: 17868339
[TBL] [Abstract][Full Text] [Related]
30. Front-line chemo-immunotherapy for treating epithelial ovarian cancer: Part I CA125 and anti-CA125.
Yang ST; Chang WH; Chou FW; Liu HH; Lee WL; Wang PH
Taiwan J Obstet Gynecol; 2023 Nov; 62(6):802-808. PubMed ID: 38008497
[TBL] [Abstract][Full Text] [Related]
31. Preoperative plasma D-dimer level is a useful prognostic marker in ovarian cancer.
Yamada Y; Kawaguchi R; Iwai K; Niiro E; Morioka S; Tanase Y; Kobayashi H
J Obstet Gynaecol; 2020 Jan; 40(1):102-106. PubMed ID: 31335252
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of serum CCL18 as a potential biomarker for ovarian cancer.
Yuan L; Wan J; Huang C; Liang J; Liu M; Yue C; Li L
Cancer Biomark; 2017 Dec; 21(1):97-104. PubMed ID: 29036787
[TBL] [Abstract][Full Text] [Related]
33. The application value of the detection of the level of tissue polypeptide antigen, ovarian cancer antigen X1, cathepsin L and CA125 on the diagnosis of epithelial ovarian cancer.
Lv XL; Zhu Y; Liu JW; Ai H
Eur Rev Med Pharmacol Sci; 2016 Dec; 20(24):5113-5116. PubMed ID: 28051260
[TBL] [Abstract][Full Text] [Related]
34. Value of serum CA125 levels in patients with high-risk, early stage epithelial ovarian cancer.
Kang WD; Choi HS; Kim SM
Gynecol Oncol; 2010 Jan; 116(1):57-60. PubMed ID: 19818996
[TBL] [Abstract][Full Text] [Related]
35. CA125 nadir concentration is an independent predictor of tumor recurrence in patients with ovarian cancer: a population-based study.
van Altena AM; Kolwijck E; Spanjer MJ; Hendriks JC; Massuger LF; de Hullu JA
Gynecol Oncol; 2010 Nov; 119(2):265-9. PubMed ID: 20797777
[TBL] [Abstract][Full Text] [Related]
36. The lack of significance of Ca125 response in epithelial ovarian cancer patients treated with neoadjuvant chemotherapy and delayed primary surgical debulking.
Le T; Hopkins L; Faught W; Fung-Kee-Fung M
Gynecol Oncol; 2007 Jun; 105(3):712-5. PubMed ID: 17400284
[TBL] [Abstract][Full Text] [Related]
37. Clinical outcomes and prognostic factors of patients with epithelial ovarian cancer subjected to first-line treatment: a retrospective study of 251 cases.
Fu Y; Wang X; Pan Z; Xie X
Front Med; 2014 Mar; 8(1):91-5. PubMed ID: 24370920
[TBL] [Abstract][Full Text] [Related]
38. CA125 normalization within 60 days as an independent prognostic factor for patients with advanced epithelial ovarian cancer.
Liao YC; Ou YC; Wu CH; Fu HC; Tsai CC; Lin H
Cancer Biomark; 2021; 32(4):559-567. PubMed ID: 34397404
[TBL] [Abstract][Full Text] [Related]
39. CLIC1 and CLIC4 complement CA125 as a diagnostic biomarker panel for all subtypes of epithelial ovarian cancer.
Singha B; Harper SL; Goldman AR; Bitler BG; Aird KM; Borowsky ME; Cadungog MG; Liu Q; Zhang R; Jean S; Drapkin R; Speicher DW
Sci Rep; 2018 Oct; 8(1):14725. PubMed ID: 30282979
[TBL] [Abstract][Full Text] [Related]
40. Soluble epidermal growth factor receptor (sEGFR) [corrected] and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer.
Baron AT; Boardman CH; Lafky JM; Rademaker A; Liu D; Fishman DA; Podratz KC; Maihle NJ
Cancer Epidemiol Biomarkers Prev; 2005 Feb; 14(2):306-18. PubMed ID: 15734951
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
